The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients

Tongji University

Status: Completed

Conditions: Hyperuricemia; Disorders Associated With Peritoneal Dialysis

Study type: Observational

Funder types: Other

Identifiers

NCT02338128

FPD2015

Details and patient eligibility

About

The purpose of this study is to determine whether Febuxostat could protect cardiovascular function of peritoneal dialysis patients by lowering serum uric acid.

Full description

Patients with more than 3-month-history of peritoneal dialysis and hyperuricemia. Use Febuxostat to control their serum uric acid for 1 year. To observe the cardiovascular events of patients, and compare and evaluate the changes of heart function, heart construction, serum cardiac markers and brain natriuretic peptide (BNP) levels before and after Febuxostat treatment.

Enrollment: 50 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Peritoneal dialysis for more than 3 months with hyperuricemia.

Exclusion criteria

1. Acute hepatopathy or liver dysfunction (Aspartate transaminase and/or alanine aminotransferase exceed 2 times of normal range)
2. Heart failure (stage IV, NYHA), unstable angina, acute stroke
3. Severe lung disease or cancer
4. unable to sign the informed consent form or disagree following-up.